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Abstract
Background: Sepsis is characterized as a systemic inflammatory response that results from the inability of the
immune system to limit bacterial spread during an ongoing infection. In this condition the significant mediator of
inflammation Platelet Activating Factor (PAF) and the coagulant factor thrombin are implicated. In animal models,
treatment with PAF-antagonists or co-administration of antibiotics with recombinant-PAF-Acetylhydrolase (rPAF-AH)
have exhibited promising results. In order to examine the putative anti-inflammatory and/or antithrombotic
interactions between antibiotic treatment used in sepsis with PAF and/or thrombin, we studied the in vitro effects
of these compounds towards PAF or/and thrombin related activities and towards PAF basic metabolic enzymes.
Methods: We assessed the inhibitory effect of these drugs against PAF or thrombin induced aggregation on
washed rabbit platelets (WRPs) or rabbit Platelet Reach Plasma (rPRP) by evaluating their IC50 values. We also
studied their effect on Cholinephosphotransferase of PAF (PAF-CPT)/Lyso-PAF-Acetyltransferase (Lyso-PAF-AT) of
rabbit leukocytes (RLs), as well as on rabbit plasma-PAF-AH, the key enzymes of both de novo/remodelling PAF
biosynthesis and PAF degradation, respectively.
Results: Several antibiotics inhibited PAF-induced platelet aggregation of both WRPs and rPRP in a concentration-
depended manner, with clarithromycin, azithromycin and amikacin exhibiting the higher inhibitory effect, while
when combined they synergistically inhibited PAF. Higher concentrations of all antibiotics tested were needed in
order to inhibit PAF induced aggregation of rPRP, but also to inhibit thrombin induced aggregation of WRPs.
Concentrations of these drugs similar to their IC50 values against PAF activity in WRPs, inhibited also in vitro PAF-
CPT and Lyso-PAF-AT activities of rabbit leukocytes, while only clarithromycin and azithromycin increased rabbit
plasma-PAF-AH activity.
Conclusions: These newly found properties of antibiotics used in sepsis suggest that apart from their general
actions, these drugs may present additional beneficial anti-inflammatory and anti-coagulant effects against the
onset and establishment of sepsis by inhibiting the PAF/PAF-receptor and/or the thrombin/protease-activated-
receptor-1 systems, and/or by reducing PAF-levels through both PAF-biosynthesis inhibition and PAF-catabolism
induction. These promising in vitro results need to be further studied and confirmed by in vivo tests, in order to
optimize the efficacy of antibiotic treatment in sepsis.
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Platelet Activating Factor (PAF) is a phospholipid signal-
ling molecule of inflammation and a significant mediator
of the immune system [1,2]. PAF transmits outside-in
signals to intracellular transduction systems in a variety
of cell types, including key cells of the innate immune
and haemostatic systems: neutrophils, monocytes, and
platelets [2]. Binding of PAF on specific membrane
receptors coupled with G-proteins (PAF-receptor,
PAFR) induces several intracellular signaling pathways
that leads to auto/endo/para/juxta-crine cellular activa-
tion [3].
PAF can be synthesized by two different and distinct
enzymatic routes, namely the remodeling and the de
novo pathway [4-6]. The remodeling pathway involves a
structural modification of 1-O-ether-linked membrane
phospholipids where the action of cytoplasmic phospho-
lipase A2 yields lyso-PAF which is then acetylated by a
lyso-PAF:acetyl-CoA acetyltransferase (Lyso-PAF AT, EC
2.3.1.67) leading to the formation of PAF. In the de novo
pathway, PAF-production occurs from simple molecules
such as alkylglycerophosphate (AGP) in several steps. A
central step is the conversion of 1-O-alkyl-2-acetyl-gly-
cerol to PAF by a specific dithiothreitol-insensitive CDP-
choline: 1-alkyl-2-acetyl-sn-glycerol cholinephospho-
transferase (PAF-CPT, EC 2.7.8.16). Concerning PAF cat-
abolism the most important enzyme involved is a PAF-
specific acetylhydrolase (PAF-AH, EC 3.1.1.47), which
cleaves the short acyl chain at the sn-2 position and
forms lyso-PAF, which is biologically inactive [7].
Increased levels of PAF are implicated in several dis-
eases, mainly inflammatory but also non-inflammatory
ones [1-3], such as cardiovascular, renal and periodontal
diseases [8-11], allergy [12], diabetes [13], cancer [14],
AIDS [15] and Sepsis [16-23].
A great variety of molecules have been found to exhi-
bit an inhibitory effect on PAF-induced biological activ-
ities, acting either through their direct antagonistic/
competitive effect to PAF by binding on PAFR, or
through other indirect mechanisms [24], that have not
been fully clarified but seems to correlate with changes
in the membrane microenvironment of PAF-receptor.
Blockage of PAFR by such molecules represents a new
therapeutic approach against several of the above men-
tioned diseases including Sepsis [16-23]. In addition,
various PAF-inhibitors exhibit also the ability to in vitro
and in vivo inhibit PAF-CPT, Lyso-PAF-AT and/or to
induce PAF-AH activities [[15,25] unpublished data by
AB Tsoupras).
Pharmacological data obtained with PAF antagonists,
indicate a significant role for PAF in sepsis, septic shock
and in the priming process [16-23]. Sepsis is a systemic
inflammatory response that results from the inability of
the immune system to limit bacterial spread during an
ongoing infection. The effect of PAF antagonists in dif-
ferent models of sepsis and shock states indicates a role
for PAF in endotoxin associated lethality, activation of
inflammatory blood cells with release of mediators, car-
diovascular failure and increased vascular permeability,
as well as in the development of shock organs and
organ failure.
The precise role of PAF as mediator of the diffuse
inflammatory state characteristic of sepsis remains to be
determined, but, in animal models, beneficial effects
have been observed as a result of treatment with various
antagonists of PAF [16-23]. Strategies to block inflam-
matory mediators such as PAF, often with complicated
outcomes, are currently being investigated as new adju-
vant therapies for sepsis. To date, however, it has been
impossible to duplicate these encouraging results from
animal models in the clinical setting.
On the other hand, administration of recombinant
PAF-AH (rPAF-AH), protects mice from inflammatory
injury and death after administration of lipopolysacchar-
ide (LPS) or cecal ligation and puncture (CLP) [26]. Co-
administration of antibiotics together with rPAF-AH
was more effective than single treatment with either of
these agents [26]. The beneficial effects of this combined
treatment suggest a potential role of antibiotics against
PAF implication in sepsis.
In order to examine the possible interactions between
PAF and antibiotic treatment against sepsis we studied
their potential effect on PAF-metabolism and/or their
putative anti-PAF activity.
For this reason in the present study we examined for
the first time the in vitro anti-inflammatory and anti-
thrombotic ability of a broad-spectrum of antibiotics
and several of their combinations/regimens used in
treatment against sepsis, based on their effect towards
PAF-induced or thrombin induced platelet aggregation
of Washed Rabbit Platelets (WR P s )a n dr a b b i tP l a t e l e t
Reach Plasma (rPRP). In addition we examined their
ability to affect PAF-metabolism by decreasing PAF-
activity, through their in vitro effect on PAF basic meta-
bolic enzymes, PAF-CPT and lyso PAF-AT of rabbit
leukocytes as well as rabbit plasma PAF-AH.
Materials and methods
Materials and instruments
Centrifugations were performed in an Heraeus Labofug
400R and a Sorvall RC-5B refrigerated super speed cen-
trifuge Homogenizations were conducted in a superso-
nic sonicator (Sonics & Materials, Newtown, CT, USA).
The liquid scintillation counter used was a 1209 Rack-
beta (Pharmacia, Wallac, Finland). PAF-induced platelet
aggregation studies were performed in a model 400 VS
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coupled to a Chrono-Log recorder at 37°C with constant
stirring at 1200 rpm.
BSA (bovine serum albumin), PAF (1-O-hexadecyl-2-
acetyl-sn-glycero-3-phosphocholine), thrombin, trichlor-
oacetic acid (TCA), CDP-choline, lyso-PAF, acetyl-CoA,
dithiothreitol (DTT), EDTA, MgCL2, Tris and analytical
reagents and solvents were purchased from Sigma (St.
Louis, MO, USA). 1-O-hexadecyl-2-[
3H]acetyl-sn-gly-
cerol-3-phosphocholine ([
3H] PAF) with a specific activ-
ity of 10 Ci/mmol was obtained from New England
Nuclear (Dupont, Boston, MA, USA). 1-O-alkyl-2-sn-
acetyl-glycerol (AAG) was purchased from BIOMOL
International LP (Palatine House, Matford Court, Exeter,
UK). 2,5-Diphenyloxazole (PPO) and 1,4-bis(5-phenyl-2-
oxazolyl) benzene (POPOP) were purchased from BDH
Chemicals (Dorset, England). Scintillation liquid cocktail
(dioxane base) was prepared by diluting 7 g PPO, 0.3 g
POPOP and 100 g Napthalene in 200 mL H2O and then
transferred to 1 L of dioxane. Liquid chromatography
grade solvents and silica G for TLC were purchased
from Merck KGaA (Darmstadt, Germany).
The antibiotics that were tested were provided by our
hospital pharmacy and were dissolved in 2.5 mg bovine
serum albumin (BSA)/mL saline [1,15]. In order to test
several combinations of antibiotic regimens, several mix-
tures of these drugs were also prepared using the above
solutions of each drug. The ratios of the concentrations
(μg/μL )o ft h ea c t i v ec o m p o n e n t st h a tw e r eu s e di n
each mixture are shown in Table two.
Biological assays on Washed Rabbit Platelets (WRPs) and
rabbit Platelet Reach Plasma (rPRP)
We assessed the in vitro inhibitory effect of these drugs
and their combinations in anti-septic treatment regi-
mens against PAF-induced or thrombin induced aggre-
gation on WRPs and rPRP by evaluating the
concentration (μg/mL) of the bioactive compound(s) in
each case in the aggregometer cuvette that inhibited
50% PAF-induced or thrombin induced aggregation
(IC50) of WRPs or rPRP, as previously described
[1,15,27,28]. Briefly, PAF and the examined drugs were
dissolved in 2.5 mg BSA/ml saline. The drugs were
tested for their ability to inhibit PAF-induced aggrega-
tion of WRPs or rPRP and thrombin induced aggrega-
tion of WRPs and/or to induce WRPs aggregation in a
Chrono-Log aggregometer. Various concentrations of
the examined samples were added into the aggreg-
ometer cuvette 1 min prior to the addition of PAF or
thrombin. The platelet aggregation induced by PAF (4.4
×1 0
-11 Ma n d2 . 2 4×1 0
-7M, final concentration in the
aggregometer cuvette in the cases of WRPs and rPRP
respectively) or thrombin (0.01 mU in the aggregometer
cuvette in the case of WRPs) was measured as PAF-
induced or thrombin induced aggregation in WRPs or
rPRP before (considered as 0% inhibition) and after the
addition of various concentrations of the examined sam-
ple [15,27,28]. A linear plot of inhibition percentage
(ranging from 20% to 80%) versus the concentration of
the sample was established for each antibiotic and in
each case. From this curve, the concentration of the
sample that inhibited 50% of the PAF or thrombin
induced aggregation (IC50) was calculated. The aggrega-
tory activity of the sample was expressed as micrograms
of the bioactive compound(s) of the drugs dissolved in
2.5 mg BSA/ml saline, which is able to induce 50% of
the maximum reversible aggregation of the respective
sample, defined as EC50 value. In addition, desensitiza-
tion tests were carried out as previously described
[15,27]. Briefly, in desensitization and cross-desensitiza-
tion experiments, platelets were activated by the addi-
tion of PAF or drugs to the platelet suspension at a
concentration that caused reversible aggregation. Second
stimulation with the tested bioactive compound(s) or
PAF respectively, was performed immediately after com-
plete disaggregation.
Isolation of plasma and leukocytes from rabbit blood
The isolation of plasma and leukocytes from rabbit
blood was performed as previously described [15] with
some modifications. Briefly: 9 mL of blood were
obtained from each rabbit in 1 mL of an anticoagulant
solution of sodium citrate/citrate acid.
The sample was centrifuged at 630 g for 10 min at 25°
C (1st centrifugation). The supernatant (plasma reach in
platelets) was centrifuged at 1400 g for 20 min at 25°C
(2nd centrifugation).
The supernatant of the 2nd centrifugation (plasma)
was aliquoted and stored at -80°C until the time of the
plasma PAF-AH assay analysis.
From the pellet of the 1st centrifugation (leukocytes
and erythrocytes) the isolation of the leukocytes from
the contaminating erythrocytes was achieved by erythro-
cyte sedimentation. Saline was added in order the sam-
ple reached its initial volume of 10 mL. The sample was
separated in half and 1.7 mL of dextran solution (3%
dextran in NaCl 0.15 M) was added in each half and the
mixtures were kept for 1 h at room temperature. The
leukocyte-rich supernatants were then centrifuged at
500 g for 10 min at room temperature (4th centrifuga-
tion). Contaminating erythrocytes of the sediment were
lysed with the addition of a lysis solution consisting of
155 mM NH4Cl, 10 mM KHCO3,a n d0 . 1m ME D T A
and then removed with a centrifugation at 300 g for10
min at room temperature (5th centrifugation).
The pelleted cells of the 5th centrifugation (isolated
leukocytes) were resuspended in 1 ml of a buffer con-
taining 50 mM Tris-HCl (pH 7.4) and sonicated on ice
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min at 4°C (6th centrifugation) in order to remove
whole cells, nucleuses and debris in the pellet and the
supernatants (homogenates) after protein determination
were aliquoted and stored at -80°C until the time of the
PAF-CPT and Lyso-PAF-AT assays analysis.
DTT-insensitive PAF-Cholinephosphotransferase (PAF-CPT)
activity assays
Assay was performed on the homogenates of rabbit leu-
kocytes as previously described [15,25]. Briefly, the reac-
t i o nw a sc a r r i e do u ta t3 7 ° Cf o r2 0m i ni naf i n a l
volume of 200 μL containing 0.05-2.5 mg/mL protein,
100 mM Tris-HCl (pH 8.0), 15 mM dithiothreitol
(DTT), 0.5 mM EDTA, 20 mM MgCl2,1m g / m LB S A ,
100 μMC D P - C h o l i n ea n d1 0 0μΜ 1-O-alkyl-2-sn-
acetyl-glycerol (AAG). The reaction was stopped by add-
ing 0,5 ml of cold methanol (2% acetic acid). The
extraction, purification and determination of PAF were
performed as previously described [25]. Briefly, 0,25 ml
of cold chloroform was added in order to firstly reach
the proportion of 1/2/0.8 CHCl3:MeOH:H2O, and after
potent vortex another 0,25 ml of cold chloroform and
0,25 ml of water were added in order to finally reach
the proportion of 1/1/0.9 CHCl3:MeOH:H2Of r o m
where produced PAF was extracted in the chloroform
phase by the acid Bligh-Dyer method [29]. The
extracted PAF was further separated by thin-layer chro-
matography (TLC) on Silica Gel G coated plates with an
elution system consisting of chloroform:methanol:acetic
acid: water (100:57:16:8, v/v/v/v). The band correspond-
ing to PAF (between lyso-phosphatidylcholine and phos-
phatidylcholine) was identified by co-chromatographing
lipid standards which were visualized by exposure of the
plates to iodine vapors. PAF fractions were scrapped off,
extracted by the Bligh-Dyer method [29] and the
amount of PAF was determined by the washed rabbit
platelet aggregation assay [1]. All assays were performed
in duplicate. Enzymatic activities were expressed as spe-
cific activity in nmol/min/mg of total protein.
The effect of drugs on PAF-CPT activity was evalu-
ated in homogenates of rabbit leukocytes. The in vitro
enzymatic assay of PAF-CPT was performed in the pre-
sence of several concentrations of each drug in the assay
reaction mixture as previously described [15].
Lyso-PAF-AT activity assays
Assay was performed on the homogenates of leukocytes
as previously described [15]. Briefly, the reaction was
carried out at 37°C for 30 min in a final volume of 200
μL containing 0.05-2.5 mg/mL protein, 50 mM Tris-
HCl (pH 7,4), 0.25 mg/mL BSA, 20 μΜ Lyso-PAF and
200 μΜ acetyl-CoA. The reaction was stopped by add-
ing 2% acetic acid methanol and the extraction,
purification and determination of PAF was carried out
as mentioned above in the PAF-CPT-assay [25]. All
assays were performed in duplicate. Enzymatic activities
were expressed as specific activity in nmol/min/mg of
total protein.
The effect of drugs on Lyso-PAF-AT activity was also
evaluated in homogenates of rabbit leukocytes. The in
vitro enzymatic assay of Lyso-PAF-AT was performed in
the presence of several concentrations of each drug in
the assay reaction mixture as previously described [15].
Plasma PAF-AH activity assays
Plasma-PAF-AH activity was determined by the trichlor-
oacetic acid precipitation method using [
3H]-PAF as a
substrate as previously described [30]. Briefly, 2 μLo f
plasma were incubated with 4 nmol of [
3H] PAF (20 Bq
per nmol) for 30 min at 37°C in a final volume of 200
μL of 50 mM Tris/HCl buffer (pH 7.4). The reaction
was terminated by the addition of cold trichloroacetic
acid (10% final concentration). The samples were then
placed in an ice bath for 30 min and subsequently cen-
trifuged at 16000 g for 5 min. The [
3H]-acetate released
into the aqueous phase was measured on a liquid scintil-
lation counter. All assays were performed in duplicate.
T h ee n z y m ea c t i v i t yw a se x p r e s s e da sn m o lo fP A F
degraded per min per mL of plasma.
The effect of drugs on PAF-AH activity was evaluated
in rabbit plasma. The in vitro enzymatic assay of plasma
PAF-AH was performed in the presence of several con-
centrations of each drug in the assay reaction mixture
as previously described [15].
Analytical methods
Protein concentrations, determined according to the
method of Bradford [31], were based on BSA as the pro-
tein standard.
Statistical analysis
Normal distribution of variables was checked using Kol-
mogorov-Smirnov criterion before further analyses. Data
are expressed as geometrical mean with 95% confidence
limits along with median, minimum and maximum
values for IC50 values and as mean values ± SD for
enzyme activities. Differences in PAF-metabolic enzymes
activities in the presence and in the absence (control) of
d r u g sw e r ea s s e s s e db ym u l t i p l ec o m p a r i s o n sw i t ho n e
way ANOVA using LSD post-hoc tests and were consid-
ered to be statistically significant when p < 0.05. Data
were analyzed using a statistical software package, SPSS
18.0, and Microsoft Excel 2007 for Windows.
Results
Several antibiotics inhibited in vitro PAF induced aggre-
gation of washed rabbit platelets in a concentration-
dependant manner. Their IC50 values against PAF are
expressed as micrograms/mL (μg/mL) of bioactive
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inhibition of PAF-induced washed rabbit platelet aggre-
gation in a final concentration of 4.4 × 10
-11 M
(Table 1). The IC50 values ranged from 0.19 to 110.95
μg/mL, approximately. The most potent ones in the
rank were clarithromycin, azithromycin, linezolid, ami-
cacin and netilmycin. Other drugs studied such as mer-
openem and vancomycin, did not influence PAF activity
in WRPs.
From all antibiotics tested, only vancomycin, induced
aggregation in WRPs in a concentration much higher
than its IC50 value (Table 1). Desensitization and cross
desensitization experiments showed that vancomycin
seemed to induce platelet aggregation through a differ-
ent way than that of PAF pathway (Table 1).
All antibiotics were further tested for their potential
inhibitory effect against the PAF-induced rabbit PRP
aggregation. Their IC50 values in this case are also
expressed as micrograms/mL (μg/mL) of bioactive com-
pound in the aggregometer cuvette that cause 50% inhi-
bition of PAF-induced aggregation of rPRP in a final
concentration of 2.24 × 10
-7 M( T a b l e2 ) .T h e s eI C 50
values ranged from 8.3 to 829.0 μg/mL, approximately.
In the case of rPRP the most potent antibiotics in the
rank were amicacin, azithromycin, tygecycline and clari-
thromycin, while other drugs studied such as merope-
nem and linezolid, did not influence PAF activity in
rPRP.
All antibiotics were also tested for their potential inhi-
bitory effect towards the thrombin induced WRP’s
aggregation. Their IC50 values in this case are also
expressed as micrograms/mL (μg/mL) of bioactive com-
pound in the aggregometer cuvette that cause 50%
inhibition of thrombin-induced aggregation of WRPs in
a final concentration of 0.01 mU (Table 3). These IC50
values ranged from 6.7 to 350.3 μg/mL, approximately.
In this case, the most potent antibiotics in the rank
were netilmicin, azithromycin, amicacin and daptomy-
cin, while again meropenem did not influence thrombin
activity in WRPs.
Several combinations of these drugs were also tested
against PAF-induced aggregation of WRPs. The most
potent ones are presented in Table 4. Among the com-
binations of antibiotics of regimens against sepsis that
were tested, piperacillin-tazobactam/netilmicin, pipera-
cillin-tazobactam/amikacin, ceftazidime/amikacin,
ceftazidime/netilmicin displayed the higher inhibitory
effect against PAF activity in WRPs, respectively
(Table 4).
In addition when these drugs were added, in concen-
trations similar to their IC50 values against PAF activity,
in the enzymatic assays of both PAF-CPT and Lyso-
PAF-AT of rabbit leukocytes they in vitro significantly
inhibited both enzymes activities in a concentration
depended manner (p < 0.05 in relevance to control
assays). In Figures 1 and 2 are shown the amounts of
each drug that induced approximately fifty to one hun-
dred inhibitory effect against PAF-CPT and Lyso-PAF-
AT specific activities respectively (Figures 1, 2). More-
over, the amount of clarithromycin needed in order to
achieve this inhibition in both PAF-CPT and Lyso-PAF-
AT was found one order of magnitude lower than those
of all the other antibiotics, with the exception of that of
amikacin in the case of Lyso-PAF-AT inhibition, which
in turn was also much lower than those of all the other
antibiotics tested.
Table 1 In vitro inhibitory effect (expressed as IC50) of the antibiotics tested against PAF-induced aggregation of WRPs
and their ability to induce platelet aggregation
IC50
1 towards PAF in WRPs (μg/mL)
Bioactive
Compound
Median Min Max Geometric
Mean
95% Confidence Interval Drug-induced WRPs aggregation/
desensitization
Clarithromycin 0.18 0.14 0.28 0.19 0.08 thru 0.46 -/-
Azithromycin 0.40 0.20 0.85 0.41 0.07 thru 2.46 -/-
Linezolid 1.25 0.60 1.62 1.07 0.30 thru 3.84 -/-
Amikacin 2.73 1.50 4.55 2.65 0.67 thru 10.54 -/-
Netilmicin 2.80 1.45 4.70 2.67 0.62 thru 11.56 -/-
Daptomycin 5.01 2.88 7.22 4.71 1.49 thru 14.85 -/-
Piperacillin/
Tazobactam
17.65/
2.22
12.18/
1.54
22.27/
2.85
16.85/2.14 7.91 thru 35.90/0.99 thru
4.61
-/-
Ceftazidime 30.06 20.92 37.95 28.79 13.66 thru 60.68 -/-
Tigecycline 113.45 91.86 131.07 110.95 71.16 thru 173.0 -/-
Vancomycin ND - - - - +/-
Meropenem ND - - - - -/-
Experiments were conducted three times using different platelets preparations.
1IC50 values are expressed as μg/mL of bioactive compound in the aggregometer
cuvette, Final concentration of PAF in the aggregometer cuvette when tested in WRPs was 4.4 × 10
-11M. WRPs: Washed Rabbit Platelets; ND: Not detected
inhibition against PAF-induced platelet aggregation; -/-: Not detected platelet aggregation; +/-: Detected platelet aggregation/not detected platelet
desensitization against PAF.
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clarithromycin and azithromycin induced an in vitro sig-
nificant increase of rabbit plasma PAF-AH (p < 0.05 in
relevance to control assays), in concentrations of an
order of magnitude higher than their IC50 values against
PAF. In Figure 3 are shown the amounts of these two
drugs that induced the significant increase of rabbit
plasma PAF-AH enzyme activity (Figure 3). Moreover,
the amount of clarithromycin needed in order to achieve
this induction in plasma-PAF-AH was found one order
of magnitude lower than that of azithromycin (p < 0.05)
Discussion
Sepsis is a systemic inflammatory response that results
from the inability of the immune system to limit bacterial
spread during an ongoing infection. The pathophysiology
of sepsis is not completely understood. Bacteria are the
main cause of sepsis. Activated receptors of the innate
immune system lead to an exaggerated immune response
including systemic inflammation. Immune cells including
activated neutrophils and macrophages express and are
controlled by a variety of cytokines, chemokines, comple-
ment factors and other mediators such as PAF and
Thrombin [16-23,32]. The activation of toll-like receptors
such as TLR4 usually leads to further amplification of
inflammation through these mediators [32]. These recep-
tors have been found to be directly activated by bacteria
Lipopolysaccharide (LPS) and thus inducing PAF bio-
synthesis by the phosphorylation and subsequently activa-
tion of Lyso-PAF-AT enzyme activity [33].
Table 2 In vitro inhibitory effect (expressed as IC50) of the antibiotics tested against PAF-induced aggregation of rPRP
IC50
1 towards PAF in rPRP (μg/mL)
Bioactive
Compound
Median Min Max Geometric Mean 95% Confidence Interval
Clarithromycin 49.6 33.2 78.4 50.5 17.4 thru 147.1
Azithromycin 23.3 11.9 29.6 20.2 6.2 thru 65.2
Linezolid ND - - - -
Amikacin 9.6 5.4 11.2 8.3 3.2 thru 21.7
Netilmicin 384.6 365.9 430.4 392.7 319.4 thru 482.9
Daptomycin 384.5 375.8 465.8 406.8 303.5 thru 545.2
Piperacillin/Tazobactam 837.1/86.4 765.0/76.9 889.6/102.3 829.0/87.9 686.5 thru 1001.0/61.6 thru 125.6
Ceftazidime 385.5 345.6 412.9 380.3 304.3 thru 475.3
Tigecycline 26.0 20.8 27.3 24.6 17.1 thru 35.2
Vancomycin 70.9 62.1 73.7 68.7 55.0 thru 86.0
Meropenem ND - - - -
Experiments were conducted three times using different platelets preparations.
1IC50 values are expressed as μg/mL of bioactive compound in the aggregometer
cuvette. Final concentration of PAF in the aggregometer cuvette when tested when tested in rPRP was 2.24 × 10
-7M. rPRP: rabbit Platelet Reach Plasma; ND: Not
detected inhibition against PAF-induced platelet aggregation.
Table 3 In vitro inhibitory effect (expressed as IC50) of the antibiotics tested against thrombin induced aggregation of
WRPs
IC50
1 towards Thrombin in WRPs (μg/mL)
Bioactive
Compound
Median Min Max Geometric Mean 95% Confidence Interval
Clarithromycin 105.6 88.3 119.5 103.7 71.0 thru 151.3
Azithromycin 13.6 11.9 14.5 13.3 10.3 thru 17.1
Linezolid 98.0 93.0 110.1 100.1 80.8 thru 124.1
Amikacin 22.0 18.7 27.3 22.4 14.0 thru 36.0
Netilmicin 6.6 5.7 8.1 6.7 4.3 thru 10.4
Daptomycin 42.7 33.7 45.9 40.4 27.1 thru 60.4
Piperacillin/Tazobactam 142.3/17.8 123.6/15.6 170.1/20.8 144.1/17.9 96.8 thru 214.4/12.5 thru 25.7
Ceftazidime 99.2 82.8 115.3 98.2 65.0 thru 148.3
Tigecycline 262.0 222.7 311.6 262.9 173.2 thru 399.1
Vancomycin 354.0 312.7 388.5 350.3 267.3 thru 459.2
Meropenem ND - - - -
Experiments were conducted three times using different platelets preparations.
1IC50 values are expressed as μg/mL of bioactive compound in the aggregometer
cuvette. Final concentration of thrombin in the aggregometer cuvette was 0.01 mU in WRPs. WRPs: Washed Rabbit Platelets; ND: Not detected inhibition against
thrombin-induced platelet aggregation.
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Page 6 of 11Both PAF and thrombin are implicated in severe
inflammatory and coagulant procedures occurring dur-
ing sepsis [24,32]. In addition it has been recently pro-
posed that in chronic pathological states such as in
cancers like melanoma, the PAF- and thrombin-acti-
vated pathways are interrelated, thus regulating, for
instance, both the melanoma cell adhesion and its
metastasis [34,35]. Critically ill patients often have sys-
temic activation of both inflammation and coagulation
[32]. Increasing evidence points to an extensive cross-
talk between these two systems, whereby inflammation
not only leads to activation of coagulation, but
coagulation also considerably affects inflammatory activ-
ity [32]. The intricate relationship between inflammation
and coagulation may have major consequences for the
pathogenesis of microvascular failure and subsequent
multiple organ failure, as a result of severe infection and
the associated systemic inflammatory response.
Beneficial effects have been observed as a result of
treatment with various inhibitors or antagonists of PAF
in different shock states and animal models [16-23]. To
date, however, it has been impossible to translate these
encouraging results from animal models in the clinical
setting.
Table 4 In vitro inhibitory effect (expressed as IC50) of the most potent combinations of antibiotic anti-septic regimens
against PAF-induced WRPs aggregation
IC50
2 towards PAF in WRPs (μg/mL)
Combinations of Bioactive Compounds Ratio
1 Median Min Max Geometric Mean 95% Confidence Interval
Piperacillin-Tazobactam/Netilmicin 40-5/1 5.1-0.6/0.1 4.6-0.6/0.1 5.3-0.7/0.1 5.0-0.6/0.1 4.2 thru 6.0-0.5 thru 0.8/0.1 thru 0.1
Piperacillin-Tazobactam/Amikacin 40-5/1.7 5.1-0.6/0.2 4.6-0.6/0.2 5.4-0.7/0.2 5.1-0.6/0.2 4.2 thru 6.1-0.5 thru 0.8/0.2 thru 0.2
Ceftazidime/Amikacin 6/1 10.0/1.7 7.4/1.2 13.1/2.6 9.9/1.7 4.9 thru 20.1/0.7 thru 4.6
Ceftazidime/Netilmicin 10/1 10.6/1.1 7.8/0.8 14.3/1.4 10.6/1.1 5.0 thru 22.5/0.5 thru 2.2
Meropenem/Netilmicin 10/1 15.3/1.5 12.2/1.2 21.4/2.1 15.9/1.6 7.9 thru 32.0/0.8 thru 3.1
Meropenem/Amikacin 6/1 22.5/3.8 18.8/3.1 31.9/5.3 23.8/4.0 12.2 thru 46.4/2.0 thru 7.8
Experiments were conducted three times using different platelets preparations.
1Ratio of concentrations of bioactive compounds in each mixture.
2IC50 values are
expressed as μg/mL of each antibiotic in the mixture that was added in the aggregometre cuvette. Final concentration of PAF in the aggregometer cuvette when
tested in WRPs was 4.4 × 10
-11M. WRPs: Washed Rabbit Platelets.
Figure 1 In vitro inhibitory effect of antibiotics towards PAF-
CPT enzyme activity of rabbit leukocytes. The amounts of each
drug that induced approximately fifty to one hundred inhibitory
effects against PAF-CPT specific activity are expressed as μg of each
bioactive compound added in the assay mixture/μL of assay
volume. PAF-CPT specific activity of rabbit leukocytes is expressed as
nmol of produced PAF/min/mg of total protein in assay. Control
signifies PAF-CPT specific activity of rabbit leukocytes in the absence
of any drug. Results are the average of three independent
determinations using different enzyme preparations performing
duplicate samples. (* p < 0.05 compared to control). PAF-CPT:
Cholinephosphotransferase of PAF.
Figure 2 In vitro inhibitory effect of antibiotics towards Lyso-
PAF-AT enzyme activity of rabbit leukocytes. The amounts of
each drug that induced approximately fifty to one hundred
inhibitory effects against Lyso-PAF-AT specific activity are expressed
as μg of each bioactive compound added in the assay mixture/μL
of assay volume. Lyso-PAF-AT specific activity of rabbit leukocytes is
expressed as nmol of produced PAF/min/mg of total protein in
assay. Control signifies Lyso-PAF-AT specific activity of rabbit
leukocytes in the absence of any drug. Results are the average of
three independent determinations using different enzyme
preparations performing duplicate samples. (* p < 0.05 compared to
control).
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promising results from an anti-PAF approach in several
diseases have been focused in an effort not only to inhi-
bit PAF action but also to down regulate its levels,
through the inhibition of its biosynthesis and/or induc-
tion of its degradation [14,15,25,26]. For example,
administration of rPAF-AH, protects mice from inflam-
matory injury and death after administration of lipopoly-
saccharide (LPS) or cecal ligation and puncture (CLP)
[26]. Co-administration of antibiotics together with
rPAF-AH was more protective than single treatment
with either of these agents [26].
To our knowledge there are no other studies on the
possible anti-inflammatory and anti-thrombotic proper-
ties of antibiotics used in sepsis treatment through their
anti-PAF or anti-thrombin activities. This is the first
study to report the anti-inflammatory and anti-thrombo-
tic activities of a wide spectrum of antibiotics through
their effects on PAF biological activities and its metabo-
lism, as well as on thrombin. We also studied the effect
of several of their combinations of treatment regimens
in sepsis, against PAF activity.
In this study, in the case of the anti-PAF activities of
the antibiotics tested, the biological assays were focused
on the PAF-induced aggregation of both WRP’sa n d
rabbit PRP. In particular, our study on WRPs probes the
anti-PAF activity of antibiotics under the experimental
conditions applied, while, in the case of rabbit PRP, the
conclusions drawn pinpoint the effect of these com-
pounds on the PAF activation, similar to the in vivo
conditions. In addition, the IC50 values measured in
each case reflect the inhibition strength of each antibio-
tic, since a low IC50 value reveals stronger inhibition of
the PAF-induced aggregation of either WRPs or rPRP
for a given antibiotic concentration.
Our work leads to the conclusion that apart from
their general anti-septic actions several antibiotics exhi-
bit also a potent in vitro inhibitory effect against PAF-
induced aggregation of both WRPs and rPRP, in a dose-
dependent manner (Tables 1 and 2). Significantly higher
concentrations (at least one order of magnitude) of each
compound were needed in order to inhibit the PAF-
induced aggregation of rabbit PRP, compared to those
needed in order to inhibit the corresponding aggregation
of WRPs.
I nt h ec a s eo fW R P st h ea n t i b i o t i c sw i t ht h em o s t
prominent anti-PAF activity were clarithromycin, azi-
thromycin, linezolid, amikacin and netilmicin, while in
the case of rPRP were amikacin, azithromycin, tigecy-
cline and clarithromycin. These results suggest that
from all antibiotics tested in both WRPs and rPRP, the
same three amikacin, azithromycin and clarithromycin,
belonged to the ones with the most potent anti-PAF
effect, even though higher concentrations of these drugs
were needed in the case of rPRP. Only in the case of
amikacin its IC50 values towards PAF-induced aggrega-
tion of both WRPs and rPRP were at the same order of
magnitude.
Furthermore, tigecycline with one of the lowest anti-
PAF effects in WRPs exhibited a potent anti-PAF effect
in the case of rPRP; only in this antibiotic its IC50 value
towards PAF-induced aggregation of rPRP was approxi-
mately 5 times lower than that towards PAF-induced
aggregation of WRPs. On the other hand, in the cases of
linezolid and netilmicin with potent anti-PAF effects in
WRPs, the first antibiotic did not inhibited PAF-induced
aggregation of rPRP at all, while the second one exhib-
ited one of the lowest anti-PAF effects in this case.
However, some of these drugs such as meropenem
and vancomycin, did not influence PAF activity in
WRPs, while the first one did not also inhibited PAF-
induced aggregation of rPRP at all. Moreover, vancomy-
cin induced in vitro aggregation of washed rabbit plate-
lets, while cross-desensitization experiments showed
that this platelet activation seems to take place through
a different way than that of PAF-PAFR pathway.
It should also be noted that the anti-PAF activity of
these drugs in WRPs was found similar to the most
potent of other antimicrobial drugs that have been
recently found to exhibit anti-PAF activity [15]. The
IC50 values of these antibiotics against PAF share same
Figure 3 In vitro effect of antibiotics towards rabbit plasma
PAF-AH enzyme activity. The amounts of each drug that induced
significant increase on specific activity are expressed as μg of each
bioactive compound added in the assay mixture/μL of assay volume
(p < 0.05 versus control). Rabbit plasma PAF-AH specific activity is
expressed as nmol of degraded PAF/min/mg of total protein in
assay. Control signifies rabbit plasma PAF-AH specific activity of
rabbit leukocytes in the absence of any drug. Results are the
average of three independent determinations using different
enzyme preparations performing duplicate samples. (* p < 0.05
compared to control). Plasma PAF-AH: plasma PAF-Acetylhydrolase
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the relatively IC50 values of some of the most potent
PAF receptor-specific antagonists used in several models
against sepsis and other diseases, such as WEB2170,
BN52021, and rupatadine [18,36,37] (0.009, 0.013, and
0.106 μg/mL in the aggregometer cuvette, respectively).
Moreover, some of these drugs seem to act synergisti-
cally against PAF-induced platelet aggregation in some
but not in all combinations of treatment regimens
against sepsis that were tested (Table 4). For example,
when ceftazidime with the one of the lowest anti-PAF
activity in WRPs (IC50 =2 8 . 7 9μg/mL) was combined
with either netilmicin with an IC50 value of 2.67 μg/mL
or with amikacin with an IC50 value of 2.65 μg/mL, the
final mixture inhibited PAF-induced platelet aggregation
with IC50 values of 10.6/1.1 μg/mL of the first or 9.9/1.7
μg/mL of the second mixture in the aggregometer cuv-
ette respectively (Table 4). The synergistic anti-PAF
action of these antibiotics when combined seems to
belong to a more general pattern, since other antimicro-
bial drugs also when combined have been found to
synergistically inhibit PAF [15]. It should be noted that
the selection of antibiotic regimens tested was based on
doses of these drugs that are usually administrated in
patients, as well as from the IC50 values of each drug
against PAF activity.
All antibiotics were additionally tested on the throm-
bin induced aggregation of WRPs. In the present study
we have found also for the first time that several of
these antibiotics exhibit additionally anti-thrombotic
properties by inhibiting thrombin induced aggregation
of WRPs in a concentration depended manner (Table
3). The antibiotics with the most prominent anti-throm-
bin activity were netilmicin and again azithromycin and
amikacin. However, significantly higher concentrations
(at least one order of magnitude, with the exception of
netilmicin) of each compound were needed in order to
inhibit the thrombin-induced aggregation of WRPs,
compared to those needed in order to inhibit the corre-
sponding PAF-induced aggregation of WRPs (Tables 1
a n d2 ) .T h i sr e s u l tp o i n t so u tt h a tW R P sw e r ea c t u a l l y
viable and still normally functioning after incubation
with concentrations of these antibiotics near their IC50
values towards PAF under the experimental conditions
used, given that when platelets were incubated with
much higher concentrations of these drugs they were
aggregated normally when thrombin was used (in con-
centrations lower than their IC50 values towards
thrombin).
In addition since much higher concentrations of these
antibiotics were needed in order to 50% inhibit throm-
b i ni nW R P s ,i ts e e m st h a tt h e s ed r u g se x h i b i tam o r e
general anti-inflammatory action, which, however, is
more specific towards the PAF-related pathway. Only in
the case of netilmicin its IC50 value towards thrombin
was in the same order of magnitude with that towards
PAF; approximately 2 folds higher than that towards
PAF. As a result this antibiotic exhibited the most
potent inhibition towards thrombin, suggesting that
netilmicin exhibits a more general anti-inflammatory
and anti-thrombotic activity, since it can inhibit both
the PAF and thrombin-related activities in concentra-
tions in the same order of magnitude.
Taking into account all the above, one may suggest
that apart from their general activities including their
beneficial effects in sepsis, some of these drugs exhibit
also a remarkable in vitro inhibitory effect against PAF
or thrombin activities, while others did not affect PAF
or thrombin activities, implying different perspectives
for each antibiotic towards inflammatory and coagulant
manifestations that usually occur during sepsis [21,32].
The observed differences between all drugs’ inhibitory
effects towards PAF and thrombin activities in different
platelet preparations, WRPs and rPRP, point out dissim-
ilar anti-inflammatory and/or anti-thrombotic potentials
for each antibiotic and may be related to differences in
their chemical structures and/or in their interactions
with cell-membranes and/or plasma constituents.
Furthermore, in order to determine the possible inter-
actions between these drugs and PAF metabolism, the
in vitro effect of some of these drugs on the activities of
PAF metabolic enzymes PAF-CPT, Lyso-PAF-AT and
PAF-AH was also studied. For this purpose, we evalu-
ated the specific activities of PAF-CPT and Lyso-PAF-
AT of homogenates of rabbit leukocytes, as well as rab-
bit plasma PAF-AH in the presence of each antibiotic in
the assay mixture. We found for the first time that sev-
eral of the antibiotics tested inhibited in vitro both PAF
biosynthetic enzymes in a concentration depended man-
ner (Figures 1 and 2), while only clarithromycin and azi-
thromycin induced an in vitro increase of rabbit plasma
PAF-AH, in concentrations an order of magnitude
higher than those of PAF-biosynthesis inhibition and
their IC50 values against PAF (Figure 3).
Smaller amounts (one to two order of magnitude) of
clarithromycin were needed in order to fifty to one hun-
dred inhibit PAF-CPT and Lyso-PAF-AT specific activ-
ities, in relevance to the other drugs tested. This result,
aided by the facts that this antibiotic seems to induce
PAF-degradation in lower concentrations than the other
antibiotics tested and potently inhibit PAF-induced pla-
telet aggregation, propose a promising role for this drug
as far as concerns its potent anti-inflammatory activity
in sepsis.
Moreover, the amounts of all antibiotics that were
needed in order to fifty to one hundred inhibit Lyso-
PAF-AT specific activity were twice higher than those
for the relevant inhibition of PAF-CPT, except for
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Page 9 of 11amikacin, where lesser amounts were needed. This
r e s u l tm a yb eas i g no fi r r e c o ncilable differences in the
inhibitory effect of these antibiotics against the two dis-
tinct biosynthetic routes of PAF. Taking also into
account that amikacin exhibited one of the most potent
anti-PAF effects (this antibiotic was the only one that its
low IC50 values were in the same order of magnitude
towards PAF-induced aggregations of both WRPs and
rPRP) and one of the most potent anti-thrombotic
effects, the additional potent inhibitory effect of this
antibiotic towards PAF-biosynthesis provide new anti-
inflammatory potentials for this drug.
Taking into account that during sepsis PAF synthesis
is induced by bacteria LPS through toll-like receptors
[33], the inhibitory effect of some of these drugs against
PAF biosynthetic enzymes may reduce PAF-synthesis,
down regulating thus PAF-activity and subsequently
PAF-related inflammatory procedures.
Conclusions
This is the first study to bring in surface putative anti-
inflammatory and anti-thrombotic activities of some
antibiotics used in sepsis, through their in vitro studied
anti-PAF and anti-thrombin effects in rabbit platelets.
Furthermore, these drugs have exhibited the ability to
inhibit also PAF-synthesis. Amicacin, clarithromycin and
azithromycin with the most potent anti-PAF activities in
both WRPs and rPRP, showed the most potent inhibi-
tory effect also towards PAF-biosynthesis, while clari-
thromycin and azithromycin were the only ones that
could induce PAF-degradation. Amikacin also inhibited
potently thrombin.
It seems that these newly found anti-inflammatory and
anti-thrombotic properties of antibiotics and/or antibio-
tic regimens used in sepsis, such as their inhibitory
activities towards PAF/PAFR and thrombin pathways, as
well as their interactions with PAF-metabolism, may
provide new perspectives for these drugs towards also
the inflammatory and coagulant manifestations that
usually take place during several septic stages, including
induced by severe sepsis multiple organ failure.
However, more in vitro and in vivo tests in animal
models are needed in order to confirm which of the
antibiotic regimens used in sepsis may exhibit the most
potent anti-inflammatory effect through the highest in
vivo inhibitory effect against PAF activities and bio-
synthesis, with simultaneously induction of PAF-degra-
dation, in an effort to increase our understanding of the
clinical implications of PAF inhibition with regard to
septic shock, severe sepsis and induced multiple organ
failure. In another point of view, the simultaneous co-
administration of antibiotic regimens with specific PAF
antagonists/drugs and/or recombinant PAF-AH should
also be considered and may augment the efficacy of
antibiotic treatment of sepsis.
T h ep r e s e n ts t u d yi st h ef i r s ts t e pi nt h i sd i r e c t i o n ,
while combined with the outcomes of the future in vivo
studies it may optimize the efficacy of antibiotic treat-
ment in inflammatory septic conditions.
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